Sign Up Now
Enter email to be notified when the new shipment of Omni-Logic PLUS is available.
Gut-Liver Axis
The gut and liver communicate bidirectionally through the biliary tract, portal vein and systemic circulation. For its part, the liver communicates with the intestines through the release of bile acids and active molecules. In the intestine,metabolic products of friendly, resident gut microbes also influence liver function.
Clinical studies have demonstrated the gut-liver and detoxification power of OMNi-BiOTiC® Hetox with outcomes including improved liver function and cardiometabolic parameters as well as decreased toxin load.
"Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis"
Year Published: 2016
Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox
Stable cirrhotic patients received Omni-Biotic Hetox or placebo for 6 months and were followed for an additional 6 months. The probiotic group demonstrated increased liver function.
"Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial"
Year Published: 2017
Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox
Adult TD2M patients were treated with Omni-Biotic Hetox (Barrier) or placebo. The probiotic intervention group demonstrated significant improvement in waist-hip ratio and HOMA-IR (insulin resistance).
"Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial"
Year Published: 2018
Study Type: double blind, randomized controlled trial
Related Omni-Biotic Formulation: Hetox
Adult TD2M patients were treated with Omni-Biotic Hetox (Barrier) or placebo. The probiotic intervention group demonstrated significantly decreased levels of endotoxin, glucose, insulin resistance, triglycerides, total cholesterol and total/HDL-cholesterol ratio compared to the placebo group.
"The gut-liver axis and the intersection with the microbiome"
Year Published: 2018
Study Type: review article
Related Omni-Biotic Formulation: Hetox
This review discusses gut-liver communications in various forms of liver disease and the potential to use the microbiome to determine the stage of liver disease as well as predicting the effects of dietary and pharmaceutical interventions.